Next Article in Journal
Non-Response to Antibiotic Treatment in Adolescents for Four Common Infections in UK Primary Care 1991–2012: A Retrospective, Longitudinal Study
Next Article in Special Issue
From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials
Previous Article in Journal / Special Issue
Techniques for Screening Translation Inhibitors
Article Menu

Article Menu

Open AccessReview

Ribosomal Antibiotics: Contemporary Challenges

Department of Structural Biology, Weizmann Institute, Rehovot 76100, Israel
Author to whom correspondence should be addressed.
Academic Editor: Claudio O. Gualerzi
Antibiotics 2016, 5(3), 24;
Received: 13 April 2016 / Revised: 7 June 2016 / Accepted: 20 June 2016 / Published: 29 June 2016
(This article belongs to the Special Issue Inhibitors of the Translational Apparatus)
Most ribosomal antibiotics obstruct distinct ribosomal functions. In selected cases, in addition to paralyzing vital ribosomal tasks, some ribosomal antibiotics are involved in cellular regulation. Owing to the global rapid increase in the appearance of multi-drug resistance in pathogenic bacterial strains, and to the extremely slow progress in developing new antibiotics worldwide, it seems that, in addition to the traditional attempts at improving current antibiotics and the intensive screening for additional natural compounds, this field should undergo substantial conceptual revision. Here, we highlight several contemporary issues, including challenging the common preference of broad-range antibiotics; the marginal attention to alterations in the microbiome population resulting from antibiotics usage, and the insufficient awareness of ecological and environmental aspects of antibiotics usage. We also highlight recent advances in the identification of species-specific structural motifs that may be exploited for the design and the creation of novel, environmental friendly, degradable, antibiotic types, with a better distinction between pathogens and useful bacterial species in the microbiome. Thus, these studies are leading towards the design of “pathogen-specific antibiotics,” in contrast to the current preference of broad range antibiotics, partially because it requires significant efforts in speeding up the discovery of the unique species motifs as well as the clinical pathogen identification. View Full-Text
Keywords: multi-drug resistance; microbiome; species-specific antibiotics susceptibility; novel degradable antibiotics multi-drug resistance; microbiome; species-specific antibiotics susceptibility; novel degradable antibiotics
Show Figures

Graphical abstract

MDPI and ACS Style

Auerbach-Nevo, T.; Baram, D.; Bashan, A.; Belousoff, M.; Breiner, E.; Davidovich, C.; Cimicata, G.; Eyal, Z.; Halfon, Y.; Krupkin, M.; Matzov, D.; Metz, M.; Rufayda, M.; Peretz, M.; Pick, O.; Pyetan, E.; Rozenberg, H.; Shalev-Benami, M.; Wekselman, I.; Zarivach, R.; Zimmerman, E.; Assis, N.; Bloch, J.; Israeli, H.; Kalaora, R.; Lim, L.; Sade-Falk, O.; Shapira, T.; Taha-Salaime, L.; Tang, H.; Yonath, A. Ribosomal Antibiotics: Contemporary Challenges. Antibiotics 2016, 5, 24.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop